Developing a new treatment for Idiopathic Pulmonary Fibrosis
Translating a Novel Therapeutic Approach to the Treatment for Idiopathic Pulmonary Fibrosis
This study is testing a new drug called VSR-H5 that aims to help people with Idiopathic Pulmonary Fibrosis (IPF) by targeting only the damaged areas of their lungs, with the hope of improving their health without causing the side effects that come with current treatments.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vasarya Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Camden, United States) |
| Project ID | NIH-10915918 on NIH RePORTER |
What this research studies
This research aims to create a novel drug candidate specifically designed to treat Idiopathic Pulmonary Fibrosis (IPF), a serious and currently incurable lung disease. The approach focuses on a compound called VSR-H5, which targets only the fibrotic areas of the lungs in patients, avoiding damage to healthy tissues. The research will involve testing this compound in laboratory settings and animal models to assess its effectiveness and safety. By selectively inhibiting the activation of harmful cells involved in fibrosis, this treatment hopes to improve patient outcomes without the severe side effects associated with existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Idiopathic Pulmonary Fibrosis who are seeking alternative treatment options.
Not a fit: Patients with other forms of lung disease or those who do not have a diagnosis of Idiopathic Pulmonary Fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for patients suffering from Idiopathic Pulmonary Fibrosis.
How similar studies have performed: While there have been advancements in IPF treatments, this specific approach using the VSR-H5 compound is novel and has not been extensively tested in clinical settings.
Where this research is happening
Camden, United States
- Vasarya Therapeutics, INC. — Camden, United States (Active)
Researchers
- Principal investigator: Hu, Ping — Vasarya Therapeutics, INC.
- Study coordinator: Hu, Ping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.